These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 37978936

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z, Mitran B, Rosenström U, Velikyan I, Rosestedt M, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Orlova A.
    Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
    [Abstract] [Full Text] [Related]

  • 5. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M.
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [Abstract] [Full Text] [Related]

  • 6. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D, Xu YP, Yang RH, Wang L, Chen F, Luo S, Yang M, Yan Y.
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [Abstract] [Full Text] [Related]

  • 7. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP.
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [Abstract] [Full Text] [Related]

  • 8. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
    Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu L, Miao Y, Reynolds TS, Smith CJ.
    Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
    Läppchen T, Kiefer Y, Holland JP, Bartholomä MD.
    Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
    [Abstract] [Full Text] [Related]

  • 10. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 11. A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor-Positive Prostate Cancer.
    Bratanovic IJ, Zhang C, Zhang Z, Kuo HT, Colpo N, Zeisler J, Merkens H, Uribe C, Lin KS, Bénard F.
    J Nucl Med; 2022 Mar; 63(3):424-430. PubMed ID: 34301778
    [Abstract] [Full Text] [Related]

  • 12. Preparation and preclinical evaluation of a 68Ga-labelled c(RGDfK) conjugate comprising the bifunctional chelator NODIA-Me.
    Läppchen T, Holland JP, Kiefer Y, Bartholomä MD.
    EJNMMI Radiopharm Chem; 2018 Mar; 3(1):6. PubMed ID: 29756024
    [Abstract] [Full Text] [Related]

  • 13. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B, Varasteh Z, Selvaraju RK, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Rosenström U, Orlova A.
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [Abstract] [Full Text] [Related]

  • 14. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
    Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, Buchegger F, Reubi JC, Maecke HR.
    J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.
    Bandara N, Stott Reynolds TJ, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ.
    Nucl Med Biol; 2018 Oct; 62-63():71-77. PubMed ID: 29929115
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
    Varasteh Z, Aberg O, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Antoni G, Sandström M, Tolmachev V, Orlova A.
    PLoS One; 2013 Oct; 8(12):e81932. PubMed ID: 24312607
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and Evaluation of the First 68Ga-Labeled C-Terminal Hydroxamate-Derived Gastrin-Releasing Peptide Receptor-Targeted Tracers for Cancer Imaging with Positron Emission Tomography.
    Wang L, Kuo HT, Chen CC, Chapple D, Colpo N, Ng P, Lau WS, Jozi S, Bénard F, Lin KS.
    Molecules; 2024 Jun 28; 29(13):. PubMed ID: 38999054
    [Abstract] [Full Text] [Related]

  • 19. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
    Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ.
    Nucl Med Biol; 2012 Apr 28; 39(3):377-87. PubMed ID: 22226021
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.